June industry news: US FDA advisory panel votes against MDMA-assisted therapy for PTSD

In June’s industry round-up: Takeda announces positive Phase IIb trial data for narcolepsy drug; an FDA advisory panel votes against the use of MDMA in therapy; Alchemab secures funding for novel antibody for Parkinson’s disease; Sanofi announces positive Phase II data for multiple sclerosis drug; and Esai and Biogen launch lecanemab in China. Take a look at May's headlines below: Takeda announces positive Phase IIb results for narcolepsy drug FDA advisory panel votes against psychedelic-based therapy for PTSD Alchemab secures funding for novel antibody with potential in Parkinson’s disease Sanofi multiple sclerosis drug reduces key nerve-damage biomarker in Phase II...